# SURE-02 (NCT05535218)

> Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05535218
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Claudia Guerrieri
- Conditions: Muscle-invasive Urothelial Carcinoma of the Bladder
- Interventions: Sacituzumab govitecan is a humanized mAb with a hydrolysable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors, whi
- Enrollment: 48
- Primary outcome: Clinical CR-rate

## Commentary we found

- X threads: 38
- YouTube: 3
- Podcasts: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=sure-02-nct05535218

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05535218", "email": "<work email>"}; the inbox owner confirms by the emailed link.